FLT3 and acute myeloid leukemia: Similarly, the Canadian Leukemia Study Group/Groupe canadien d’étude sur la leucémie (CLSG/GCEL) consensus recommends all newly diagnosed (ND)-AML adults undergo molecular assessment including FLT3 [25].